Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DANTE: Duration of Anti-PD1 therapy for melanoma
ISRCTN15837212Phase 4Completed
- Sponsor
- Sheffield Teaching Hospitals NHS Foundation Trust
- Start
- Aug 2018
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes, Monoclonal Antibodies → Antibody-Based Therapeutics
01
Overview
Phase 4, randomised, open-label trial of pembrolizumab and nivolumab in melanoma (2 arms), sponsored by Sheffield Teaching Hospitals NHS Foundation Trust. Primary endpoint: Progression-free survival. Started Aug 2018; status: completed.
02
Drugs
03
Conditions
melanoma
Beyond the preview
Go deeper on ISRCTN15837212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ISRCTN15837212.